Cargando…
Resensitization of methicillin-resistant Staphylococcus aureus by amoxapine, an FDA-approved antidepressant
The rapid increase in bacterial resistance to antibiotics is a global healthcare crisis. Non-antibiotic pharmaceuticals that have attained approval by the United States Food and Drug Administration have the potential to be repurposed as bacterial resistance-modifying agents and therefore could becom...
Autores principales: | Wilson, Tyler J., Blackledge, Meghan S., Vigueira, Patrick A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5767979/ https://www.ncbi.nlm.nih.gov/pubmed/29349359 http://dx.doi.org/10.1016/j.heliyon.2017.e00501 |
Ejemplares similares
-
FDA-Approved Amoxapine Effectively Promotes Macrophage Control of Mycobacteria by Inducing Autophagy
por: Wang, Jia, et al.
Publicado: (2022) -
Bicarbonate Resensitization of Methicillin-Resistant Staphylococcus aureus to β-Lactam Antibiotics
por: Ersoy, Selvi C., et al.
Publicado: (2019) -
Synergistic Combinations of FDA-Approved Drugs with Ceftobiprole against Methicillin-Resistant Staphylococcus aureus
por: Sharma, Amar Deep, et al.
Publicado: (2022) -
Diclofenac Resensitizes Methicillin‐Resistant Staphylococcus aureus to β‐Lactams and Prevents Implant Infections
por: Zhang, Shutao, et al.
Publicado: (2021) -
Molecular docking-based screening of methicillin-resistant Staphylococcus aureus FEM proteins with FDA-approved drugs
por: Akkiraju, Anjini Gayatri, et al.
Publicado: (2023)